CN103146620A - 具有益生菌特性的脆弱拟杆菌 - Google Patents
具有益生菌特性的脆弱拟杆菌 Download PDFInfo
- Publication number
- CN103146620A CN103146620A CN2013100951267A CN201310095126A CN103146620A CN 103146620 A CN103146620 A CN 103146620A CN 2013100951267 A CN2013100951267 A CN 2013100951267A CN 201310095126 A CN201310095126 A CN 201310095126A CN 103146620 A CN103146620 A CN 103146620A
- Authority
- CN
- China
- Prior art keywords
- bacteroides fragilis
- probiotics
- bacterium
- probiotic
- cfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及微生物应用技术领域,具体涉及一种具有益生菌特性的脆弱拟杆菌,本发明是从发育良好的婴儿粪便中分离纯化得到具有益生菌特性的脆弱拟杆菌,实验证明该脆弱拟杆菌对动物无害,属于益生菌,可用于制备含有这种微生物的食物或药品。
Description
技术领域
本发明涉及微生物应用技术领域,具体涉及一种具有益生菌特性的脆弱拟杆菌。
背景技术
益生菌系一种对动物有益的细菌,它们可直接作为食品添加剂服用,以维持肠道菌丛的平衡。当人体住满足够的益生菌时,人就会处于健康的状态,但是一旦体内菌群失去平衡,比如菌种间比例发生大幅变化或者超出正常数值时,那么腹泻、过敏、胃口不佳、疲倦、免疫力低等一系列病症就会随之而来,人体的健康就会亮红灯,而这时适当添加益生菌,协助体内菌群平衡,才能让人重现健康状态。
在益生菌中,被广泛关注的双歧杆菌和乳酸菌在摄入后对人和动物具有很好作用的菌株,它们的特定菌株能够在肠粘膜上定居,在肠道内建群并且防止有害微生物在其上粘附,是能通过保持肠内自然微生物区系促进生物个体健康的可生长的微生物制剂,帮助维持人和动物的健康。文件CN1350460A公开了一种能够预防腹泻的乳酸菌菌株;文件CN1420781A公开了一种能够预防腹泻的双歧杆菌。
脆弱拟杆菌(Bacteroides fragilis)作为一种革兰氏染色阴性、杆状、两端钝圆而浓染,有荚膜、无芽胞、无动力的专性厌氧细菌,分产肠毒素型和非产肠毒素型。脆弱拟杆菌作为人及动物肠道正常菌群的一部分,主要存于结肠中,此外,呼吸道、胃肠道及泌尿生殖道粘膜也可定植生长。目前研究较多的是脆弱拟杆菌作为一种条件致病菌,当宿主粘膜受损时,可侵犯粘膜下层,引起感染,也可经血液流动,引起身体其它器官如肠道、腹腔、肝、肺、脑组织化脓性感染并伴发脓肿和引起急慢性腹泻等。此外,其对结肠、直肠癌的发生也有促进作用。
发明内容
本发明的目的是提供一种具有益生菌特性的脆弱拟杆菌。
为了解决上述问题,本发明所采用的技术方案是:
提供一种具有益生菌特性的脆弱拟,所述的脆弱拟杆菌保藏单位名称为中国微生物菌种保藏管理委员会普通微生物中心,保藏单位地址为北京市朝阳区北辰西路1号院3号,保藏日期为2013年3月12日,保藏编号为CGMCC NO.7280,分类命名为Bacteroides fragilis。
该菌株16SrRNA具有SEQ ID NO:1所示的核苷酸序列,序列长度为887bp。
本发明的有益效果是:本发明是从发育良好的婴儿粪便中分离纯化得到具有益生菌特性的脆弱拟杆菌,实验证明分离得到的脆弱拟杆菌对动物无害,属于益生菌,可用于制备含有这种微生物的食物或药品。
附图说明
图1为本发明的具有益生菌特性的脆弱拟杆菌的实施例1的菌落形态的示意图。
图2为本发明的具有益生菌特性的脆弱拟杆菌的实施例1的显微镜下的菌落形态示意图。
图3为本发明的具有益生菌特性的脆弱拟杆菌的实施例1的BLAST序列比对结果图。
具体实施方式
下面通过实施例对本发明做进一步详细说明,这些实施例仅用来说明本发明,并不限制本发明的范围。
实施例1 脆弱拟杆菌CGMCC NO .7280 的分离纯化
(1)由婴儿粪便中分离脆弱拟杆菌CGMCC NO .7280
按“正常菌群检查法”称取0.5克大便,置于先装有4.5ml生理盐水的试管中,以此连续稀释成10-1~10-6,由高稀积度向低稀积度滴到Bd培养基平板上,置于厌氧产气盒中加厌氧产气袋进行厌氧培养。置37℃,2~7天后开罐检查。选单一菌落进行纯培养、染色镜检、培养特性、生理生化检测。
菌落形态如图1所示。
显微镜观察如图2所示。
(2)脆弱拟杆菌CGMCC NO.7280的16SrRNA基因进行序列检测
所得16SrRNA序列如下:
GAGTCGCTACAGCCTTCGATGGATAGGGGTTCTGAGAGGAAGGTCCCCCACATTGGAACTGAGACACGGTCCAAACTCCTACGGGAGGCAGCAGTGAGGAATATTGGTCAATGGGCGCTAGCCTGAACCAGCCAAGTAGCGTGAAGGATGAAGGCTCTATGGGTCGTAAACTTCTTTTATATAAGAATAAAGTGCAGTATGTATACTGTTTTGTATGTATTATATGAATAAGGATCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGATCCGAGCGTTATCCGGATTTATTGGGTTTAAAGGGAGCGTAGGTGGACTGGTAAGTCAGTTGTGAAAGTTTGCGGCTCAACCGTAAAATTGCAGTTGATACTGTCAGTCTTGAGTACAGTAGAGGTGGGCGGAATTCGTGGTGTAGCGGTGAAATGCTTAGATATCACGAAGAACTCCGATTGCGAAGGCAGCTCACTGGACTGCAACTGACACTGATGCTCGAAAGTGTGGGTATCAAACAGGATTAGATACCCTGGTAGTCCACACAGTAAACGATGAATACTCGCTGTTTGCGATATACAGTAAGCGGCCAAGCGAAAGCATTAAGTATTCCACCTGGGGAGTACGCCGGCAACGGTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGAGGAACATGTGGTTTAATTCGATGATACGCGAGGAACCTTACCCGGGCTTAAATTGCAGTGGAATGATGTGGAAACATGTCAGTGAGCAATCACCGCTGTGAAGGTGCTGCATGGTTGTCGTCAGCTCGTGCCGTGAGGTGTCGGCTTAAGTGCCATAACGAGCGCAACCCTTATCTTTAGTTACTAACAGTTATGCTGAGGACTCTAGAGAGCTG(SEQ ID NO:1)。
(4)进行BLAST序列比对
结果如图3所示。
(5)脆弱拟杆菌CGMCC NO.7280的增菌培养及菌液制备
选取纯化后的单个菌落接种于改良的胰蛋白胨肉汤中进行增菌培养,所得菌液离心沉淀,转速3000r/min,离心15min,去上清,沉淀物用生理盐水洗涤后,沉淀物用生理盐水稀释,用麦氏比浊管做菌数测定,稀释至108 cfu /ml,109 cfu /ml,1010 cfu /ml,保存备用。
实施例2 脆弱拟杆菌毒力实验
采用实施例1制备的脆弱拟杆菌菌液进行以下实验:
(1)小鼠急性毒力实验
取体重22±2克C57BR/C小鼠(雌雄各半)60只,分成高剂量组、低剂量组和对照组,各组20只。高剂量组每只小鼠每天灌胃1012 cfu /ml菌液0.5ml,低剂量组每天灌胃109 cfu /ml菌液0.5ml,对照组每天灌胃0.5ml生理盐水。连续观察14天。
实验结果:小鼠正常生长,未见死亡,LD50测不出。
(2)大鼠毒力实验
取150±20克SD大鼠30只(雌雄各半),分为3组:高低剂量组和对照组。高剂量组每只大鼠每天灌胃1012cfu/ml菌液2ml,低剂量组每天灌胃109cfu/ml菌液2ml,对照组每天灌胃2ml生理盐水。连续观察14天,14天后抽静脉血测血象、肝肾功。取胃肠肝脾组织做病理切片电镜观察。
实验结果:均未见明显异常。
(3)恒河猴毒力实验
取恒河猴10只(雌雄各半),分为2组:高低剂量组和对照组。高剂量组每只恒河猴每天口服1012cfu/ml菌液100ml,低剂量组每天口服109cfu/ml菌液100ml。连续观察60天。14天、30天、45天、60天后分别抽静脉血测血象、肝肾功,测心电图。取胃肠肝脾组织做病理切片电镜观察。
实验结果:均未见明显异常。
实验结果说明,本发明分离得到的脆弱拟杆菌CGMCC NO.7280对动物无毒害作用,属于益生菌。
Claims (2)
1.具有益生菌特性的脆弱拟杆菌,其特征在于:所述脆弱拟杆菌保藏编号为CGMCC NO.7280。
2.如权利要求1所述的具有益生菌特性的脆弱拟杆菌,其特征在于:该菌株16SrRNA具有SEQ ID NO:1所示的核苷酸序列,序列长度为887bp。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100951267A CN103146620A (zh) | 2013-03-25 | 2013-03-25 | 具有益生菌特性的脆弱拟杆菌 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100951267A CN103146620A (zh) | 2013-03-25 | 2013-03-25 | 具有益生菌特性的脆弱拟杆菌 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103146620A true CN103146620A (zh) | 2013-06-12 |
Family
ID=48544943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100951267A Pending CN103146620A (zh) | 2013-03-25 | 2013-03-25 | 具有益生菌特性的脆弱拟杆菌 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103146620A (zh) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103404707A (zh) * | 2013-08-19 | 2013-11-27 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备预防动物肠道疾病的组合物中的应用 |
WO2017071346A1 (zh) * | 2015-10-29 | 2017-05-04 | 广州知易生物科技有限公司 | 脆弱拟杆菌在抗水产病原菌中的应用 |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
CN111635874A (zh) * | 2020-06-05 | 2020-09-08 | 江南大学 | 一株能够调控肠道阿克曼菌属相对丰度的脆弱拟杆菌 |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
US12048720B2 (en) | 2017-06-14 | 2024-07-30 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1029857C (zh) * | 1990-05-03 | 1995-09-27 | 张季阶 | 拟杆菌微生态制剂的制备方法 |
CN101177712A (zh) * | 2006-11-10 | 2008-05-14 | 佳能株式会社 | 探针、探针组、固定有探针的载体和基因检测方法 |
CN103156886A (zh) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备治疗细菌性阴道炎组合物中的应用 |
-
2013
- 2013-03-25 CN CN2013100951267A patent/CN103146620A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1029857C (zh) * | 1990-05-03 | 1995-09-27 | 张季阶 | 拟杆菌微生态制剂的制备方法 |
CN101177712A (zh) * | 2006-11-10 | 2008-05-14 | 佳能株式会社 | 探针、探针组、固定有探针的载体和基因检测方法 |
CN103156886A (zh) * | 2013-03-18 | 2013-06-19 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备治疗细菌性阴道炎组合物中的应用 |
Non-Patent Citations (1)
Title |
---|
CERDENO-TARRAGA,A.M ET AL: "NCTC 9343 16S ribosomal RNA, complete", 《GENBANK》 * |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
CN103404707A (zh) * | 2013-08-19 | 2013-11-27 | 广州知光生物科技有限公司 | 脆弱拟杆菌在制备预防动物肠道疾病的组合物中的应用 |
US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
WO2017071346A1 (zh) * | 2015-10-29 | 2017-05-04 | 广州知易生物科技有限公司 | 脆弱拟杆菌在抗水产病原菌中的应用 |
US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
US12048720B2 (en) | 2017-06-14 | 2024-07-30 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
CN111635874A (zh) * | 2020-06-05 | 2020-09-08 | 江南大学 | 一株能够调控肠道阿克曼菌属相对丰度的脆弱拟杆菌 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103146620A (zh) | 具有益生菌特性的脆弱拟杆菌 | |
CN111235070B (zh) | 一株母乳婴儿源植物乳杆菌bf_15及其应用 | |
CN108004189A (zh) | 一种复合益生乳酸菌粉剂及其制备方法与应用 | |
CN112175864B (zh) | 动物双歧杆菌及其选育方法和应用 | |
CN102453689B (zh) | 一株产胞外多糖的植物乳杆菌及其应用 | |
CN102533588B (zh) | 一株产胞外多糖的短乳杆菌及其应用 | |
CN104232515B (zh) | 一种动物双歧杆菌及其应用 | |
WO2017020784A1 (zh) | 一种脆弱拟杆菌及其应用 | |
CN113337431B (zh) | 一株抑制幽门螺杆菌的罗伊氏乳杆菌nsl0501及其生物菌剂和应用 | |
CN103156888A (zh) | 脆弱拟杆菌在制备治疗炎症性肠病组合物中的应用 | |
BR112012011315A2 (pt) | cepa de bifidobactéria probiótica | |
CN106754579A (zh) | 一种凝结芽孢杆菌及其用途 | |
CN104805040B (zh) | 一种枯草芽孢杆菌制剂及制备方法和应用 | |
CN105420150A (zh) | 一种嗜酸乳杆菌及其应用 | |
CN104531549A (zh) | 一种可调节肠道运动、预防便秘的发酵乳杆菌Lactobacillus fermentum zhao及其用途 | |
Ghatani et al. | Assessment of probiotic characteristics of lactic acid bacteria isolated from fermented yak milk products of Sikkim, India: Chhurpi, Shyow, and Khachu | |
CN104430847A (zh) | 发酵乳杆菌Lactobacillus fermentum Lee工作发酵剂制品及其预防便秘保健用途 | |
CN112625979A (zh) | 一种对抗幽门螺杆菌的干酪乳杆菌及其应用 | |
CN112725219A (zh) | 一种青春双歧杆菌菌株及其应用 | |
CN105199991A (zh) | 一株水貂肺炎克雷伯氏菌 | |
CN104381440A (zh) | 发酵乳杆菌Lactobacillus fermentum Lee工作发酵剂制品及其预防便秘保健用途 | |
CN106434427A (zh) | 乳酸杆菌益生菌cgmcc no.12421及在制备降脂药物中的应用 | |
CN115381860A (zh) | 一种保护酒精性肝损伤组合物及其制备方法与应用 | |
CN114990030B (zh) | 嗜酸乳杆菌la18及其在制备调节肠道菌群或免疫调节的产品方面的应用 | |
CN103082294A (zh) | 脆弱拟杆菌在制备治疗腹泻组合物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130612 |